Teva Pharmaceutical Industries (TEVA) Innovation & Strategy Day summary

Strategic transformation and growth pillars

• Transitioning from a generics-focused company to a leading biopharma, driven by a four-pillar strategy and the 'Accelerate' phase of the Pivot to Growth strategy for 2025–2027, focusing on innovative and biosimilar medicines, generics, and operational transformation.

• Achieved nine consecutive quarters of growth, with innovative franchise CAGR ~30%, $1 billion added in innovative sales, and a clear path to $2.5 billion in AUSTEDO revenue by 2027.

• Sustained generics growth across all regions, generics powerhouse expected to remain stable at ~$9.5B through 2027, and biosimilars revenues targeted to double by 2027.

• Modernization and operational efficiency programs targeting $700 million in net savings by 2027, with two-thirds realized by end of 2026, and manufacturing network consolidation to under 30 sites by 2027.

• Assembled a world-class leadership team and strengthened executive team with industry veterans to drive execution, transformation, and capital allocation.

Innovative portfolio and pipeline execution

• Innovative revenue expected to exceed $4 billion by 2027 and $5 billion by 2030, driven by AUSTEDO, AJOVY, UZEDY, and new launches.

• Late-stage pipeline includes blockbuster candidates in neuroscience, immunology, and rare diseases, such as duvakitug (IBD), DARI (asthma), emrusolmin (MSA), and anti-IL-15 (celiac/vitiligo), with multiple launches planned through 2030.

• AUSTEDO projected to surpass $2.5B in sales by 2027, with strong adoption of once-daily XR formulation and focus on under-treated populations.

• LAI antipsychotic franchise (UZEDY and olanzapine LAI) aims for $1.5–2B peak sales, leveraging go-to-market expertise and differentiated profiles.

• R&D strategy leverages proven science, capital efficiency, and partnerships to accelerate both early and late-stage programs.

Generics, biosimilars, and operational excellence

• Generics powerhouse expected to remain stable at ~$9.5B through 2027, with launches covering 60–80% of $175B LoE value.

• Biosimilars revenues targeted to double by 2027, with 10 in-line assets and 13 in pipeline, covering ~$55B LoE value.

• OTC portfolio in EU & IM outpacing market growth, with $1.1B revenues and 100+ brands.

• Manufacturing network consolidation to under 30 sites by 2027, driving efficiency, lower COGS, and best-in-class service levels (>98%).

• Supply network transformation and lean management to drive margin expansion and competitiveness.